Abstract
Aims: Design of sulfonamide-triazine derivatives as JAK1 inhibitors. Background: JAK1 is a kinase involved in different autoimmune diseases. JAK1 inhibitors have shown promising results in treating autoimmune diseases.
Objectives: To design new JAK1 inhibitors based on sulfonamides-triazine conjugates capable of binding interactions comparable to observed interactions anchoring potent crystallographic JAK1 inhibitors.
Methods: The crystallographic structures of 4 diverse nanomolar inhibitors complexed within JAK1 were used to guide the synthesis of new diaminotriazine-sulfonamide-based JAK1 inhibitors.
Results: Nineteen compounds have been prepared, some of which exhibited low micromolar IC50 values against JAK1.
Conclusions: Crystallographic complexes of diverse JAK1 inhibitors were successfully used to guide the synthesis of novel sulfonamide-triazine-based low micromolar JAK1 inhibitors.
Keywords: JAK1 inhibitors, sulfonamides, diamino-triazines, docking, dose-response, crystallographic complexes.
Graphical Abstract
Current Computer-Aided Drug Design
Title:Design and Synthesis of New JAK1 Inhibitors based on Sulfonamide- Triazine Conjugates
Volume: 17 Issue: 7
Author(s): Safa Daoud and Mutasem O. Taha*
Affiliation:
- Department of Pharmaceutical Chemistry and Pharmacognosy, Faculty of Pharmacy, Applied Science Private University, Amman, Jordan
- Department of Pharmaceutical Sciences, Faculty of Pharmacy, University of Jordan, Amman, Jordan
Keywords: JAK1 inhibitors, sulfonamides, diamino-triazines, docking, dose-response, crystallographic complexes.
Abstract: Aims: Design of sulfonamide-triazine derivatives as JAK1 inhibitors. Background: JAK1 is a kinase involved in different autoimmune diseases. JAK1 inhibitors have shown promising results in treating autoimmune diseases.
Objectives: To design new JAK1 inhibitors based on sulfonamides-triazine conjugates capable of binding interactions comparable to observed interactions anchoring potent crystallographic JAK1 inhibitors.
Methods: The crystallographic structures of 4 diverse nanomolar inhibitors complexed within JAK1 were used to guide the synthesis of new diaminotriazine-sulfonamide-based JAK1 inhibitors.
Results: Nineteen compounds have been prepared, some of which exhibited low micromolar IC50 values against JAK1.
Conclusions: Crystallographic complexes of diverse JAK1 inhibitors were successfully used to guide the synthesis of novel sulfonamide-triazine-based low micromolar JAK1 inhibitors.
Export Options
About this article
Cite this article as:
Daoud Safa and Taha O. Mutasem *, Design and Synthesis of New JAK1 Inhibitors based on Sulfonamide- Triazine Conjugates, Current Computer-Aided Drug Design 2021; 17 (7) . https://dx.doi.org/10.2174/1573409916666201224152253
DOI https://dx.doi.org/10.2174/1573409916666201224152253 |
Print ISSN 1573-4099 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6697 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
DNA Mismatch Repair Deficiency, Resistance to Cancer Chemotherapy and the Development of Hypersensitive Agents
Current Topics in Medicinal Chemistry <i>In Vivo</i> Tracking of Novel SPIO-Molday ION Rhodamine-B™-Labeled Human Bone Marrow-Derived Mesenchymal Stem Cells After Lentivirus- Mediated COX-2 Silencing: A Preliminary Study
Current Gene Therapy Obesity, Hypertension and Hypercholesterolemia as Risk Factors for Atherosclerosis Leading to Ischemic Events
Current Medicinal Chemistry Discovery and Design of Selective Cyclooxygenase-2 Inhibitors as Non-Ulcerogenic, Anti-Inflammatory Drugs with Potential Utility as Anti-Cancer Agents
Current Drug Targets Arnica compositum, Hekla lava and Acidum Nitricum Together are Superior to Arnica compositum Alone in the Local Treatment of Symptomatic Calcific Periarthritis of the Shoulder: A Pilot Study
Reviews on Recent Clinical Trials Role of Metabolism in Ocular Drug Delivery
Current Drug Metabolism Runx2/Cbfa1: A Multifunctional Regulator of Bone Formation
Current Pharmaceutical Design Tissue Transglutaminase Expression During Neural Differentiation of Human Mesenchymal Stem Cells
CNS & Neurological Disorders - Drug Targets QSAR Study of PARP Inhibitors by GA-MLR, GA-SVM and GA-ANN Approaches
Current Analytical Chemistry Remyelination in Multiple Sclerosis: The Therapeutic Potential of Neural and Mesenchymal Stem/Progenitor Cells
Current Signal Transduction Therapy Role of Stem Cells in Colorectal Cancer Progression and Prognostic and Predictive Characteristics of Stem Cell Markers in Colorectal Cancer
Current Stem Cell Research & Therapy Peroxisome Proliferator-Activated Receptor (PPAR) in Metabolic Syndrome and Type 2 Diabetes Mellitus
Current Diabetes Reviews CD26 Inhibition Enhances Perfusion Recovery in ApoE-/-Mice
Current Vascular Pharmacology Health Benefits of Honey: Implications for Treating Cardiovascular Diseases
Current Nutrition & Food Science Coumarin and Derivates as Lipid Lowering Agents
Current Topics in Medicinal Chemistry Xanthine Oxidase and Transforming Growth Factor Beta-activated Kinase 1: Potential Targets for Gout Intervention
Current Rheumatology Reviews Inducers of Heme Oxygenase-1
Current Pharmaceutical Design Oral and Dental Considerations in the Management of Leukemic Children
Applied Clinical Research, Clinical Trials and Regulatory Affairs Anti-atherosclerotic Effects of Spice-Derived Phytochemicals
Current Medicinal Chemistry Pro-Oxidant Milieu Blunts Scissors: Insight into Tumor Progression, Drug Resistance, and Novel Druggable Targets
Current Pharmaceutical Design